Innate Pharma SA - SPONSORED ADS (IPHA)
Historical Holders from Q4 2019 to Q4 2025
-
Type / Class
-
Equity / SPONSORED ADS
-
Symbol
-
IPHA on Nasdaq
-
Price per share
-
$1.75
-
All holders as of 30 Sep 2025
-
Q3 2025
-
Total 13F shares as of 30 Sep 2025
-
81,617
-
Holdings value
-
$157,932
-
% of all portfolios
-
0%
-
Share change
-
-18,221
-
Value change
-
-$33,200
-
Average buys %
-
0%
-
Average sells %
-
-0%
-
Number of holders
-
9
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
As of 30 Sep 2025, Innate Pharma SA - SPONSORED ADS (IPHA) has 9 institutional shareholders filing 13F forms.
They hold 81,617 shares
.
Institutional Holders of Innate Pharma SA - SPONSORED ADS (IPHA) across Reporting Periods
| Period |
Reported Shares, Excl. Options |
Value, Excl. Options |
Value Change |
Puts Notional Value |
Calls Notional Value |
Price |
Investors |
|
2025 Q4
|
1,073 |
$1,878 |
-$2,114 |
|
|
$1.75 |
1 |
|
2025 Q3
|
81,617 |
$157,932 |
-$33,200 |
|
|
$1.93 |
9 |
|
2025 Q2
|
99,838 |
$179,124 |
-$103,610 |
|
|
$1.81 |
9 |
|
2025 Q1
|
158,189 |
$282,029 |
+$35,951 |
|
|
$1.78 |
10 |
|
2024 Q4
|
137,970 |
$255,200 |
-$185,233 |
|
|
$1.85 |
9 |
|
2024 Q3
|
237,742 |
$544,429 |
-$8,244 |
|
|
$2.29 |
7 |
|
2024 Q2
|
241,754 |
$469,203 |
-$47,223 |
|
|
$1.94 |
8 |
|
2024 Q1
|
253,918 |
$731,097 |
+$366,440 |
|
|
$2.88 |
9 |
|
2023 Q4
|
128,912 |
$360,800 |
-$534,506 |
|
|
$2.80 |
8 |
|
2023 Q3
|
318,407 |
$805,527 |
+$243,938 |
|
|
$2.53 |
8 |
|
2023 Q2
|
412 |
$1,000 |
-$171,049 |
|
|
$2.43 |
1 |
|
2023 Q1
|
396,953 |
$1,128,356 |
-$11,740 |
|
|
$2.85 |
8 |
|
2022 Q4
|
399,345 |
$1,489,515 |
-$839,353 |
|
|
$3.73 |
9 |
|
2022 Q3
|
779,329 |
$1,559,000 |
-$11,145 |
|
|
$2.00 |
8 |
|
2022 Q2
|
953,812 |
$2,575,000 |
-$72,850 |
|
|
$2.70 |
11 |
|
2022 Q1
|
952,242 |
$3,199,000 |
-$1,817,238 |
|
|
$3.36 |
12 |
|
2021 Q4
|
1,202,864 |
$5,489,000 |
+$1,081,290 |
|
|
$4.56 |
14 |
|
2021 Q3
|
943,114 |
$5,818,000 |
+$5,267,168 |
|
|
$6.17 |
18 |
|
2021 Q2
|
89,540 |
$296,000 |
-$324,284 |
|
|
$3.30 |
5 |
|
2021 Q1
|
176,028 |
$759,802 |
-$5,091,479 |
|
|
$4.32 |
7 |
|
2020 Q4
|
1,395,579 |
$5,707,000 |
-$1,116,727 |
|
|
$4.09 |
4 |
|
2020 Q3
|
1,683,925 |
$6,652,000 |
-$6,064,054 |
|
|
$3.90 |
6 |
|
2020 Q2
|
2,871,409 |
$20,310,000 |
-$29,641,435 |
|
|
$7.00 |
7 |
|
2020 Q1
|
7,339,905 |
$49,030,000 |
-$2,479,416 |
|
|
$6.68 |
9 |
|
2019 Q4
|
7,714,565 |
$49,665,000 |
+$49,665,212 |
|
|
$6.43 |
11 |